Sarepta Therapeutics/$SRPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Ticker
$SRPT
Sector
Primary listing
Employees
1,372
Headquarters
Website
SRPT Metrics
BasicAdvanced
$2.2B
-
-$0.60
0.49
-
Price and volume
Market cap
$2.2B
Beta
0.49
52-week high
$133.15
52-week low
$10.42
Average daily volume
6M
Financial strength
Current ratio
2.888
Quick ratio
1.443
Long term debt to equity
99.742
Total debt to equity
100.509
Interest coverage (TTM)
-0.05%
Profitability
EBITDA (TTM)
40.147
Gross margin (TTM)
22.77%
Net profit margin (TTM)
-2.34%
Operating margin (TTM)
-0.04%
Effective tax rate (TTM)
-140.17%
Revenue per employee (TTM)
$1,810,000
Management effectiveness
Return on assets (TTM)
-0.02%
Return on equity (TTM)
-4.76%
Valuation
Price to revenue (TTM)
0.878
Price to book
1.62
Price to tangible book (TTM)
1.62
Price to free cash flow (TTM)
-4.798
Free cash flow yield (TTM)
-20.84%
Free cash flow per share (TTM)
-4.691
Growth
Revenue change (TTM)
64.89%
Earnings per share change (TTM)
-222.03%
3-year revenue growth (CAGR)
43.76%
10-year revenue growth (CAGR)
116.72%
3-year earnings per share growth (CAGR)
-53.48%
10-year earnings per share growth (CAGR)
-17.87%
What the Analysts think about SRPT
Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.
Bulls say / Bears say
FDA advisers voted 8-6 in May 2025 to support accelerated approval of Sarepta’s SRP-9001 gene therapy for Duchenne muscular dystrophy, enhancing likelihood of U.S. market entry and revenue growth. (Reuters)
Positive phase 1/2 SRP-9003 trial data showed 73% mean signal intensity and an 89% mean reduction in creatine kinase in high-dose cohorts for limb-girdle muscular dystrophy type 2E, underscoring pipeline diversification beyond DMD. (Reuters)
Collaboration with Codiak Biosciences grants Sarepta access to exosome-based platforms and up to $72.5 million in upfront and near-term payments, bolstering non-dilutive funding and pipeline expansion. (Reuters)
The European Medicines Agency declined to back Sarepta’s Elevidys gene therapy for DMD and the U.S. FDA halted all shipments, causing shares to drop nearly 13% and down 88.8% year-to-date, signaling regulatory and commercialization setbacks. (Reuters)
Elevidys was linked to the first reported fatal liver injury when a teenage boy died of acute liver failure post-treatment, intensifying safety concerns and regulatory scrutiny. (Bloomberg)
Following the death of a 51-year-old trial participant, Sarepta announced study halts and layoffs; the stock plunged 25% amid criticism over delayed disclosure and broader financial strain. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
SRPT Financial Performance
Revenues and expenses
SRPT Earnings Performance
Company profitability
SRPT News
AllArticlesVideos
What's Going On Sarepta Stock On Wednesday?
Benzinga1 week ago
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress
Business Wire2 weeks ago
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sarepta Therapeutics stock?
Sarepta Therapeutics (SRPT) has a market cap of $2.2B as of October 18, 2025.
What is the P/E ratio for Sarepta Therapeutics stock?
The price to earnings (P/E) ratio for Sarepta Therapeutics (SRPT) stock is 0 as of October 18, 2025.
Does Sarepta Therapeutics stock pay dividends?
No, Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders as of October 18, 2025.
When is the next Sarepta Therapeutics dividend payment date?
Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.